Inside the research
Eli Lilly and Company
LLY Research profile · latest available data
Price overview
$1,183.46
▲ +1.57 (+0.1%)
| 52w hi | $1,280.34 |
|---|---|
| 52w lo | $710.11 |
| Vol | 1.92M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.07
| Short | -0.15 |
|---|---|
| Medium | +0.17 |
| Long | +0.31 |
computed 2026-09-27
Key fundamentals
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
| Market cap | $1.06T |
|---|---|
| Enterprise value | $1.10T |
| Trailing P/E | 39.69x |
| Forward P/E | 25.00x |
| EV / EBITDA | 26.39x |
| P / S (ttm) | 13.24x |
| Profit margin | 33.5% |
| Return on equity | 102.3% |
| Revenue growth | +47.7% |
| Earnings growth | +26.2% |
| Debt / equity | 162.07 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.27 | |
| Sector | +0.08 | |
| Technical | -0.08 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Risk Metrics
| Beta vs SPX | 0.58 |
|---|---|
| Corr SPX | 0.25 |
| Annual vol | 37.9% |
| Annual ret | +19.7% |
| Sharpe | 0.52 |
| Max DD | -32.9% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $1,209.14 |
|---|---|
| High / Low | $1,500.00 / $850.00 |
| Median | $1,250.00 |
| Analysts | 29 |
| Strong Buy | 6 | |
|---|---|---|
| Buy | 18 | |
| Hold | 6 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-05 | Guggenheim | → Buy |
| 2026-05-05 | Barclays | → Overweight |
| 2026-05-04 | Wolfe Research | → Outperform |
| 2026-05-01 | Cantor Fitzgerald | → Overweight |
| 2026-04-22 | Guggenheim | → Buy |
| 2026-04-10 | Morgan Stanley | → Overweight |
Officers & Board
| Director | Mary Lynne Hedley since 2022 |
|---|---|
| Director | Kimberly H. Johnson since 2021 |
| Director | Gabrielle Sulzberger since 2021 |
| Director | Karen Walker since 2018 |
| CEO | David A. Ricks since 2017 |
| Director | David A. Ricks since 2017 |
| Director | Jamere Jackson since 2016 |
| Director | Juan R. Luciano since 2016 |
| Director | Marschall Stevens Runge since 2013 |
| Director | William G. Kaelin since 2012 |
| Director | Katherine Baicker since 2011 |
| Director | Ralph Alvarez since 2009 |
| Director | Erik Fyrwald since 2005 |
| Founder | Eli Lilly current |
| CEO | John C. Lechleiter 2008–2016 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-05-20 | Other Material Event, Exhibits | read |
| 2026-05-07 | Shareholder Vote | read |
| 2026-04-30 | Earnings Release, Exhibits | read |
| 2026-02-04 | Earnings Release, Exhibits | read |
| 2025-11-21 | Officer / Director Change | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-08-20 | Other Material Event, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-05-08 | Shareholder Vote | read |
| 2025-05-01 | Earnings Release, Exhibits | read |
| 2025-02-12 | Other Material Event, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Zakrowski Donald A | SVP, Finance, & CAO | Sell | 2.00K | $2.37M |
| 2026-08-07 | Hakim Anat | EVP, GC & Secretary | Sell | 5.00K | $5.95M |
| 2026-08-01 | Seymour Melissa | EVP, Global Quality | Option exercise | 981 | — |
| 2026-08-01 | Seymour Melissa | EVP, Global Quality | Withheld for tax | 439 | $504.00K |
| 2026-07-20 | Fyrwald J Erik | Grant | 9 | $9.92K | |
| 2026-07-20 | LUCIANO JUAN R | Grant | 14 | $15.92K | |
| 2026-07-20 | Sulzberger Gabrielle | Grant | 4 | $4.96K | |
| 2026-07-20 | Alvarez Ralph | Grant | 11 | $12.42K | |
| 2026-06-15 | Sulzberger Gabrielle | Grant | 4 | $4.96K | |
| 2026-06-15 | LUCIANO JUAN R | Grant | 14 | $15.92K |
Flow & Concentration
| Insider 180d net | -$24.07M |
|---|---|
| Insider buys / sells | 0 / 4 |
| Insider bias | Sellers |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
Dividends
| Yield (TTM) | 0.27% |
|---|---|
| $ / share (TTM) | $3.23 |
| 5y CAGR | +15.2% |
Annual dividend per share
| 2021 | $3.40 |
|---|---|
| 2022 | $3.92 |
| 2023 | $4.52 |
| 2024 | $5.20 |
| 2025 | $6.00 |
| 2026 | $1.73 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $229.74K | Department of Veterans Affairs | AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $45.04B | +5.1% | |
| Net income | $20.64B | +14.9% | |
| Cash from ops | $16.81B | +8.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $1,185.32 | $1,190.00 | $1,160.84 | $1,183.46 | 1.92M |
| Sep 24 | $1,156.67 | $1,197.79 | $1,151.00 | $1,181.89 | 2.42M |
| Sep 23 | $1,174.71 | $1,188.88 | $1,145.98 | $1,150.99 | 2.15M |
| Sep 22 | $1,146.15 | $1,180.53 | $1,139.26 | $1,170.14 | 2.45M |
| Sep 21 | $1,144.50 | $1,170.90 | $1,134.41 | $1,164.89 | 2.48M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →